Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0000737 (abdominal pain)
 31,184 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Today, hysterectomy internationally is nearly as frequent as appendectomy. In approx. 1% of all hysterectomies (vaginal or abdominal) where one or both ovaries are left, the residual ovary syndrome is found after an average period of slightly over five years. Predominant symptoms are diffused abdominal pain and palpable tumour of the adnexae. More rarely, only one symptom alone is found. Up to today, treatment of choice has been an operation which, due to the always present adhesions, is a severe one. The results described in this paper suggest the probatory treatment with high-dosage dept-gestagens (Depo-Provera). In 71% of the cases the tumour disappeared completely under this treatment and in 39% the pain. In further 21% a diminution of the tumour could be seen and in 41% an improvement of the pain. Only in 8% did the tumour and in 20% the pain not respond. There was no case where there was a deterioration. The proposed therapy is cheaper and less dangerous than the usual surgical treatment and therefore should always be performed probatorily before an operation.
 ...
PMID:[Residual ovary syndrome--significance of medical therapy (author's transl)]. 735 70

A study of intramuscular injections of depo medroxyprogesterone acetate (Depo Provera) as a postpartum contraceptive was undertaken in an attempt to determine the following: 1) the continuation rates for this contraceptive method in a postpartum family planning program; 2) to compare the continuation rates of Depo Provera given as a postpartum contraceptive with other postpartum contraceptive methods, as reported elsewhere; 3) the use-effectiveness of Depo Provera as a postpartum contraceptive method; 4) the side effects of postpartum injections; and 5) the reasons for discontinuation of this method. Between April 1969 and May 31, 1972 there were a total of 325 acceptors at the Family Planning Department of McCormick Hospital in Chiang Mai, Thailand. 217 of the women were acceptors of 3-month injections and 108 women were acceptors of 6-month injections. Of all acceptors, 94.2% received their 1st injection within 5 days of delivery. Cases continuing beyond 12 months were too few in number for significant statistical analysis. There were no known method failure pregnancies. Of the 325 postpartum acceptors of the 3-month and 6-month Depo Provera injections, 152 had discontinued the method by May 31, 1972. Of these, 47 were lost to follow up. The reasons for the discontinuation of the 105 remaining cases were bleeding problems (amenorrhea, prolonged, frequent or heavy bleeding, and irregular periods), other medical reasons (palpitation and dizziness, abdominal pain, pain at injection site, and melasma), and personal reasons.
 ...
PMID:Use of a long-acting injectable contraceptive in a postpartum family planning program. 1226 37

The course in laparoscopy for diagnostic and operative procedures in gynecology, part of a training program in reproductive health for medical personnel at the University of Nairobi, began in June 1979 at Kenyatta National Hospital in Nairobi, Kenya. Between its inception and February 1980, physicians attempted 85 laparoscopic sterilizations using tubal ligation technique (the Falope Ring). 4 patients underwent a minilaparotomy instead, due to complications, for a success rate of 95.3%. Physicians performed the procedure on an average of 15-20 minutes with 3-5 minutes used for attaching the rings. Only 3 of the laparoscopic patients and all of minilaparotomy patients required extra hospitalization. Most (87.1%) only required an overnight stay. 4.7% went home the same day as the procedure. The leading complaint at follow up (7 days after the procedure) was abdominal pain, but generally no medication was needed. Physicians detected wound infection in only 3 and prescribed only antibiotic treatment. Women's ages ranged from 23- 45 years. Even though most patients knew little to nothing about the procedure itself, they all knew that it was permanent and that it was what they wanted. Most women learned of sterilization from family planning clinics. Average parity was 6.4 (range 2-12). Prior to sterilization, 17.6% had never used any contraception, but of those that did, most used oral contraceptives (OCs) or OCs and Depo-Provera. The overwhelmingly leading reason for choosing sterilization was had enough children. This study showed that properly trained medical personnel can successfully perform laparoscopic tubal ligation using the Falope Ring and local anesthesia on an outpatient basis. The laprocator and other equipment must be adequately maintained for this technique to be successful, however.
 ...
PMID:Laparoscopic sterilisation at Kenyatta National Hospital, Nairobi. 1228 54

FDA has approved medroxyprogesterone acetate as Depo Provera Contraceptive Injection, effective for 3 months in preventing pregnancy in women. In clinical studies, the drug's failure rate was less than 1%. However, physicians must ensure that patients receive injections on schedule to prevent pregnancy. The recommended dose is 150 mg administered every 3 months by deep, intramuscular injection in the gluteal or deltoid muscle. Most women in clinical studies of Depo Provera experienced menstrual irregularities. As use continued, amenorrhea became common, reported by 57% of the women by the end of a year of treatment. Other side effects included weight gain, headache, nervousness, abdominal pain or discomfort, dizziness, and asthenia. Physicians should administer the drug only to women found not to be pregnant, because fetal exposure may lead to low birth weight and other problems. Recent data have demonstrated that longterm use may contribute to osteoporosis, and the drug's manufacturer, the Upjohn Company of Kalamazoo, Michigan, will conduct additional research to study this possible side effect. Contraindications are similar to those for other contraceptives and include undiagnosed vaginal bleeding, known or suspected malignancy of breast, thromboembolic disorders, cerebral vascular disease, and liver dysfunction. Depo Provera was developed in the 1960s and has been approved for contraception in many other countries. When FDA first reviewed data on the drug in the 1970s, animal studies raised questions about its potential to cause breast cancer. Since then, longterm controlled clinical studies in other countries have shown a risk of breast cancer comparable to oral contraceptives, and no increased risk for ovarian, liver, or cervical cancer. The studies also showed that the contraceptive injection reduced the risk of endometrial cancer. FDA approved the drug October 29, 1992.
 ...
PMID:3-month contraceptive injection approved. 1231 15

Molar pregnancies represent an uncommon yet important obstetric problem with potentially fatal outcomes. Patients typically present with signs and symptoms of early pregnancy, and physicians most often suspect nonmolar pregnancy complications initially; however a hydatidiform mole should be included in the differential diagnosis of a woman with a positive pregnancy test and abnormal vaginal bleeding irrespective of the use of contraception. Our case is that of an adolescent female on Depo-Provera injectable contraceptive with increased vaginal bleeding, abdominal pain, nausea, and vomiting who was incidentally found to be pregnant and subsequently diagnosed with a molar pregnancy despite persistent denial of having initiated sexual intercourse. Though gestational trophoblastic disease is uncommon with an incidence of about 1-2 cases per 1,000 pregnancies, a clinician has to display a high index of suspicion when dealing with patients at extremes of age in order to avoid potentially life-threatening outcomes.
 ...
PMID:Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera. 2811 90